At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,208 enrolled
Drug / intervention
ranibizumab +1 moredrug
Likely dose
ranibizumab 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial (CATT)
In Brief
A Phase 3 clinical trial evaluating ranibizumab and bevacizumab for Age Related Macular Degeneration. Completed, enrolled 1,208 participants across 59 sites.
Detailed Summary
The purpose of the study is to evaluate the relative efficacy and safety of treatment of neovascular AMD with Lucentis on a fixed schedule, Avastin on a fixed schedule, Lucentis on a variable schedule, and Avastin on a variable schedule. A five year follow-up visit is being conducted in 2014 to gather information on long term outcomes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAge Related Macular Degeneration
CountriesUnited States
CollaboratorsNational Eye Institute (NEI)
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 2008
Enrollment StartFeb 2008
Primary CompletionDec 2010
Study CompletionApr 2015
TodayJul 2026
First PostedJan 15, 2008
Enrollment StartFeb 1, 2008
Primary CompletionDec 1, 2010
Study CompletionApr 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 18.5 years ago
Interventions
ranibizumabdrug
• 0.5 mg (0.05 mL)intravitreal injection
bevacizumabdrug
• 1.25 mg (0.05 mL)intravitreal injection